PT  - JOURNAL ARTICLE
ED  - ,
TI  - Controlled-release budesonide in Crohn's disease
AID  - 10.1136/dtb.1997.35430
DP  - 1997 Apr 01
TA  - Drug and Therapeutics Bulletin
PG  - 30--31
VI  - 35
IP  - 4
4099  - http://dtb.bmj.com/content/35/4/30.short
4100  - http://dtb.bmj.com/content/35/4/30.full
SO  - Drug Ther Bull1997 Apr 01; 35
AB  - Relevant BNF section: 1.5Budesonide is a glucocorticoid with high local activity but much lower systemic availability than prednisolone. Topical formulations have long been licensed for use in asthma and rhinitis. Here we discuss a new orally active controlled-release preparation of budesonide (Entocort CR - Astra) formulated specifically for treating patients with Crohn's disease affecting the ileum and/or ascending colon. The manufacturer claims that the preparation "targets the ileum and ileocaecal area, achieving rapid results equivalent to prednisolone" with a "low level of systemic steroid side effects".